1
|
Zhao S, Wu L, Kuang Y, Su J, Luo Z, Wang Y, Li J, Zhang J, Chen W, Li F, He Y, Tao J, Zhou J, Xu X, Peng C, Chen X. Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression. Int J Oncol 2018; 53:2397-2408. [PMID: 30272281 PMCID: PMC6203154 DOI: 10.3892/ijo.2018.4579] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2018] [Accepted: 09/07/2018] [Indexed: 12/18/2022] Open
Abstract
Cluster of differentiation (CD)147, as a transmembrane glycoprotein, is highly expressed in a variety of tumors. Accumulating evidence has demonstrated that CD147 serves critical roles in tumor cell death and survival; however, the underlying mechanism requires further investigation. In the present study, it was revealed that CD147 knockdown significantly increased melanoma cell apoptosis. In addition, downregulation of CD147 reversed the malignant phenotype of melanoma, as demonstrated by the induction of tumor cell apoptosis in a xenograft mouse model. In addition, a human apoptosis antibody array was performed and 9 differentially expressed apoptosis-related proteins associated with CD147 were identified, including insulin-like growth factor-binding protein 2 (IGFBP2). Additionally, CD147 knockdown was observed to significantly decreased IGFBP2 expression at the mRNA and protein levels in melanoma cells. Providing that IGFBP2 is a downstream molecule in the phosphatase and tensin homolog (PTEN)/phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, the effects of CD147 on this particular pathway were investigated. Interestingly, the expression of phosphorylated (p)-AKT and p‑mechanistic target of rapamycin was attenuated, whereas PTEN was markedly upregulated in CD147-underexpressing melanoma cells. Furthermore, application of a PI3K‑specific inhibitor also decreased IGFBP2 expression. Importantly, IGFBP2 was highly expressed in clinical tissues of melanoma compared with the control group, and its expression exhibited a positive association with CD147. The present study revealed that CD147 served a critical role in mediating the apoptosis of melanoma cells via IGFBP2 and the PTEN/PI3K/AKT signaling pathway. IGFBP2 and CD147 were observed to be overexpressed in clinical melanoma tissues; IGFBP2 was shown to be positively associated with CD147 expression, suggesting that CD147 may be considered as a potential therapeutic target for chemotherapy or prevention for in melanoma.
Collapse
Affiliation(s)
- Shuang Zhao
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Lisha Wu
- Institute of Medical Sciences, Xiangya Hospital, Central South University, Changsha, Hunan 410008
| | - Yehong Kuang
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Juan Su
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Zhongling Luo
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Yan Wang
- Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, Jiangsu 210042
| | - Jinmao Li
- Department of Dermatology, Xiangya Hospital
| | - Jianglin Zhang
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Wangqing Chen
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Fangfang Li
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Yijing He
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Juan Tao
- Department of Dermatology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030
| | - Jianda Zhou
- Department of Plastic Surgery of The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P. R. China
| | - Xiaowei Xu
- Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
| | - Cong Peng
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| | - Xiang Chen
- Department of Dermatology, Xiangya Hospital
- Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital
| |
Collapse
|